AffiliationDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
MetadataShow full item record
AbstractThe cost of personalised medicine in oncology is increasing. The varied and contrasting priorities of the pharmaceutical industry, local and national governments, international medical community, and patients need to be reviewed and balanced. In addition to the economic and political standpoints on this issue, the ethical considerations from physicians' viewpoints need to be considered to optimise cancer patients' care. In this paper we discuss the way research and development (R&D) of these drugs is carried out and reimbursed, and how this needs to change. We describe frameworks assessing the value of these treatments which been developed. Physicians need to develop their knowledge and understanding of these issues to best meet their dual responsibilities of advocating for their patients and promoting public health.
CitationBalancing the economics and ethics of personalised oncology. 2018, 4(9): 608-615 Trends Cancer
JournalTrends in Cancer
- Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
- Authors: Doble B
- Issue date: 2016
- Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
- Authors: Huntington SF, Davidoff AJ, Gross CP
- Issue date: 2020 Feb 1
- Ethical considerations of neuro-oncology trial design in the era of precision medicine.
- Authors: Gupta S, Smith TR, Broekman ML
- Issue date: 2017 Aug
- Ethical Hurdles in the Prioritization of Oncology Care.
- Authors: de Groot F, Capri S, Castanier JC, Cunningham D, Flamion B, Flume M, Herholz H, Levin LÅ, Solà-Morales O, Rupprecht CJ, Shalet N, Walker A, Wong O
- Issue date: 2017 Apr
- Precision medicine ethics: selected issues and developments in next-generation sequencing, clinical oncology, and ethics.
- Authors: Fiore RN, Goodman KW
- Issue date: 2016 Jan